AGA is seeking comments from members, health care providers, consumers, public/private purchasers and other stakeholders on proposed perfomance measures. The measures were developed by AGA to help improve the quality of care and health outcomes for patients.
Performance measures are used to measure whether evidence-based treatment and surveillance guidelines are followed, as appropriate, and to assess the results of care and health outcomes.
Share your thoughts on proposed measures
These hospital inpatient measures were adapted from the AGA guideline on management of acute pancreatitis 48 – 72 hours after hospital admission.
The 30-day public comment period opened on Sept. 21, 2018, at 4 p.m. ET, and closes at 4 p.m. ET on Oct. 20, 2018. All comments will be reviewed and considered by the AGA Quality Measures Committee and responses will be published on the AGA website after the review is complete.
AGA’s role in performance measures development
AGA has been a leader in performance measurement since 2006 and has developed measures for several digestive health conditions and clinical topics including: colorectal cancer (CRC) screening and surveillance, gastroesophageal reflux disease (GERD), hepatitis C (HCV) and other liver diseases, and inflammatory bowel disease (IBD).
The AGA Institute Quality Measures Committee provides clinical and methodological expertise and oversight for the development, specification, maintenance and testing of AGA’s performance measures. Learn more.